How to buy Applied Therapeutics stock (APLT)

Applied Therapeutics is a biotechnology business based in the US. Applied Therapeutics shares (APLT) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $0.88 – a decrease of 23.47% over the previous week. Applied Therapeutics employs 37 staff and has a market cap (total outstanding shares value) of 0.00.

Our top picks for where to buy Applied Therapeutics stock

Buy Applied Therapeutics stock from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.

Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.

Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.

Applied Therapeutics stock price (NASDAQ: APLT)

Use our graph to track the performance of APLT stocks over time.

Applied Therapeutics shares at a glance

• Key figures

Information last updated 2024-12-18.

Latest market close	$0.88
52-week range	$0.95 - $10.62
50-day moving average more info button	$7.06
200-day moving average more info button	$5.92
Wall St. target price	$6.33
PE ratio more info button	N/A
Dividend yield more info button	N/A
Earnings per share (TTM) more info button	$-1.42

Is it a good time to buy Applied Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Applied Therapeutics price performance over time

Historical closes compared with the close of $1.02 from 2024-12-19

1 week (2024-12-13)	-11.30%
1 month (2024-11-21)	-89.00%
3 months (2024-09-20)	-86.75%
6 months (2024-06-21)	-77.58%

1 year (2023-12-21)	-66.99%
2 years (2022-12-21)	20.00%
3 years (2021-12-21)	9.99
5 years (2019-12-20)	24.72

Applied Therapeutics financials

Gross profit TTM	$0
Return on assets TTM	-76.01%
Return on equity TTM	-473.39%
Profit margin	0%
Book value	$0.05
Market Capitalization more info button	$125.7 million

TTM: trailing 12 months

Applied Therapeutics share dividends

We're not expecting Applied Therapeutics to pay a dividend over the next 12 months.

Applied Therapeutics share price volatility

Over the last 12 months, Applied Therapeutics's shares have ranged in value from as little as $0.95 up to $10.6237. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Applied Therapeutics's is 2.018. This would suggest that Applied Therapeutics's shares are significantly more volatile than the average for this exchange and represent a higher risk.

Applied Therapeutics overview

Applied Therapeutics, Inc. , a clinical-stage biopharmaceutical company, engages in the development of a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need in the United States. The company's lead product candidate is AT-007 (also called govorestat) that has completed phase 3 for the treatment of galactosemia in healthy volunteers and adults, in pediatric clinical study for the treatment of galactosemia in kids, for treating enzyme sorbitol dehydrogenase, and for the treatment of phosphomannomutase enzyme-CDG. It also develops AT-001 (also called caficrestat) that is in phase 3 clinical trials to treat diabetic cardiomyopathy, as well as for the treatment of diabetic peripheral neuropathy; and AT-003, which is in preclinical studies for the treatment diabetic retinopathy. The company has exclusive license and supply agreement with Mercury Pharma Group Limited to commercialize drug products containing AT-007. Applied Therapeutics, Inc. was incorporated in 2016 and is headquartered in New York, New York.

Frequently asked questions

null
What percentage of Applied Therapeutics is owned by insiders or institutions?
Currently 5.239% of Applied Therapeutics shares are held by insiders and 103.347% by institutions. How many people work for Applied Therapeutics?
Latest data suggests 37 work at Applied Therapeutics. When does the fiscal year end for Applied Therapeutics?
Applied Therapeutics's fiscal year ends in December. Where is Applied Therapeutics based?
Applied Therapeutics's address is: 545 Fifth Avenue, New York, NY, United States, 10017 What is Applied Therapeutics's ISIN number?
Applied Therapeutics's international securities identification number is: US03828A1016 What is Applied Therapeutics's CUSIP number?
Applied Therapeutics's Committee on Uniform Securities Identification Procedures number is: 03828A101